Medical Daily – Vaginal Estrogen Linked to Fewer Hospitalizations in Repeat-UTI Women

Tier 2: Professional organization or credentialed expert guidance
Publisher: Medical Daily · Published: August 11, 2026 · Accessed: August 15, 2026

Visit the source ↗

Claims this source supports

• The Urology analysis (published online July 1 2026, Epic Cosmos EHR database, lead author Brennan A. Wells) found vaginal estrogen prescription in women with recurrent UTIs was associated with lower rates of sepsis, hospitalization and death over the following years – in women over 55 with recurrent UTIs, sepsis rate was 10.6% among vaginal-estrogen users vs 19.4% among non-users, mortality 0.42% vs 1.54%, hospitalization 4.06% vs 5.16%.
• Recurrent UTI is generally defined as two infections within six months or three within a year.
• A 2025 study in JAMA Network Open found only 9% of female Medicare recipients with genitourinary syndrome of menopause who had a prescription for vaginal estrogen actually filled it – the 'most eligible patients never fill the prescription' gap.
• The FDA initiated removal of the boxed warnings from menopausal hormone therapy products in November 2025, and on February 12 2026 approved labeling changes removing cardiovascular disease, breast cancer and probable dementia risk statements for six products, including low-dose vaginal estrogen.
• Stephanie Faubion, MD (Mayo Clinic Center for Women's Health director, Menopause Society medical director, quoted via CIDRAP): vaginal forms are more effective than systemic estrogen for genitourinary symptoms, and no associated increase in breast cancer or heart disease risk with the local product; possible slightly elevated blood clot risk.
• Mechanism: after menopause, falling estrogen raises vaginal pH and lactobacilli that normally dominate vaginal and bladder tissue struggle to survive – thinning, drier tissue becomes a friendlier environment for UTI-causing bacteria.